tradingkey.logo

Merck’S Investigational Zilovertamab Vedotin At 1.75 mg/kg Dose Plus Standard Of Care Showed Promising Antitumor Activity

ReutersMay 30, 2025 12:06 PM

- Merck & Co Inc MRK.N:

  • MERCK’S INVESTIGATIONAL ZILOVERTAMAB VEDOTIN AT 1.75 MG/KG DOSE PLUS STANDARD OF CARE SHOWED PROMISING ANTITUMOR ACTIVITY, INCLUDING COMPLETE RESPONSE RATE, IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL IN PHASE 2 PORTION OF WAVELINE-003 TRIAL

  • MERCK & CO INC - ZILOVERTAMAB VEDOTIN ACHIEVES 56.3% ORR IN RELAPSED/REFRACTORY DLBCL

  • MERCK & CO INC - ZILOVERTAMAB VEDOTIN UNDER EVALUATION IN PHASE 3 AND PHASE 2 STUDIES

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI